retatrutide case study just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Full article: Efficacy and safety

Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T

This evidence challenges the conventional approach of delaying medication intervention and offers practitioners new options for tailoring obesity treatment to individual response patterns

Whether its delivered to your doorstep or picked up at a pharmacy: get it into the refrigerator ASAP

comparison (standard therapy)

Receptor activation table The triple agonism of retatrutide is more than just a matter of combining mechanisms

Clinical Trial Pipeline: 170+ Peptides in Active Development More than 170 peptides are in active clinical development, with over 280 peptide drugs undergoing preclinical and clinical studies